Search
Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers
CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and...
Sep 5, 2024
France's OSE Immunotherapeutics is moving a cancer vaccine into a second P3 trial while working on other oncology and I&I targets
CEO Nicolas Poirier describes the work, which includes an IL-7R, and partnerships with AbbVie, Boehringer Ingelheim, and Veloxis.
Sep 4, 2024
Paris based Nanobiotix has always had a nanophysics approach to medicine - the ways they are applying it could be expanding soon
Founder and CEO Laurent Levy gives an update on the company's robust radiation oncology program, and describes two new areas of...
Sep 4, 2024
The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease
Samir Ounzain explains the way HAYA studies how long non-coding RNAs, a once poorly understood component of the genome, affects disease...
Sep 4, 2024
The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead
Bobby Azamian describes how Tarsus has expanded its salesforce by 50%, and will be adding a DTC element to the launch and derive...
Sep 3, 2024
Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London
Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for...
Aug 31, 2024
Skye Bioscience's CEO Punit Dhillon discusses next generation CB1 inhibition for obesity, and flags how key data from competitor Novo coming this quarter could impact the class
He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better...
Aug 30, 2024
Health 2035 Summit: Roivant CEO Matt Gline on why he believes this is a good time to be hunting for assets on the shelves of big pharma, and upcoming catalysts
He describes why this may be a good time to asset hunt, but also why Roivant has been conservative with its cash. Plus upcoming catalysts...
Aug 27, 2024
Checking in with Artiva CEO Fred Aslan after the NK cell focused company's $167 million IPO
He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is...
Aug 15, 2024
The CEO of Praxis Precision Medicines discusses the company's CNS focus and key data that is scheduled for this year
Marcio Souza describes Praxis' small molecule and antisense oligonucleotide platforms, and previews key trials that will have near term data
Aug 14, 2024
Illumina’s CEO Jacob Thaysen shares highlights from the company’s ‘Strategy Update' today and his vision for the business going forward
Jacob Thaysen covers Illumina’s business today, including the NovaSeq X platform, multiomics, clinical and pharma industry applications,...
Aug 13, 2024
Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production
She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that...
Aug 13, 2024
Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more
Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE...
Aug 9, 2024
Nello Mainolfi shares an update on Kymera and the progress of the protein degradation field
He gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has...
Aug 9, 2024
Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer
David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer...
Aug 7, 2024
The CEO of UK based Levicept shares background on the company's neurotrophin-3 inhibiting fusion protein, which they say succeeded today in pain management in an osteoarthritis phase 2 study
Eliot Forster describes the scientific rational of inhibiting NT-3 while avoiding nerve growth factor and the side effects that come with...
Aug 6, 2024
Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome
He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic...
Aug 5, 2024
Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma
Adrian Rawcliffe describes how the treatment works, the expected rollout and cost, and what this means for TCR therapies going forward.
Aug 2, 2024
Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today
Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for...
Aug 1, 2024
io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides
CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the...
Jul 31, 2024
.png){kind=logo}
